Table 5

Enrichment of the common metastatic-signature (CMS)

Study [Reference]

Platform

Unique Genes Tested

Primary

Tumors

Distant Mets

Unique CMS Genes in dataset

Significant CMS Genes

LS Statistic

p-value

GEO Acc # or SMD Pub #


Varambally Prostate [39]

HG U133 Plus 2.0

19079

7

6

65

57

< 0.00001

GSE3325

Chen Gastric [15]

Undefined cDNA microarray

10568

89

14

61

26

< 0.00001

SMD Pub # 232

Ki Colon [21]

CMRC-GT

9078

52

28

55

25

0.00011

GSE6988

Riker Melanoma [33]

HG U133 Plus 2.0

19079

16

40

71

17

0.011

GSE7553

Linn Sarcoma [25]

Undefined cDNA microarray

14437

47

10

61

5

0.50

SMD Pub # 287

Tothill Ovarian [37]

HG U133 Plus 2.0

19079

189

54

65

7

0.93

GSE9899


The 6 validation datasets with regard to the platform used in the original experiment, the number of unique genes represented in the platform, the number of samples that are primary tumors or distant metastases (mets), the number of genes in the common metastatic signature (CMS) represented in the platform, the number of CMS genes that were significant with a Q-value < 0.1, the LS statistic p-value, and the Gene Expression Omnibus Accession number (GEO Acc #) or SMD Publication number (SMD Pub #). HG U133 Plus 2: Affymetrix Human Genome U133 Plus 2.0 Array; CMRC-GT: Cancer Metastasis Research Center-Genomic Tree array, Yonsei Cancer Center, Seoul, Korea.

Daves et al. BMC Medical Genomics 2011 4:56   doi:10.1186/1755-8794-4-56

Open Data